Elahere hcpcs

Author: jalc

August undefined, 2024

WebMar 1, 2024 · ELAHERE is a prescription medicine used to treat adults with folate receptor-alpha positive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who: have not responded to or are no longer … Web• Administer ELAHERE as an intravenous infusion only after dilution in 5% Dextrose Injection, USP. ELAHERE is incompatible with normal saline. (2.5) • The recommended dose of ELAHERE is 6 mg/kg adjusted ideal body weight administered as an intravenous infusion every 3 weeks until disease progression or unacceptable toxicity. ( 2.2)

Elahere Granted Accelerated Approval for Platinum-Resistant …

WebApr 7, 2024 · Each mL of solution contains 5 mg of mirvetuximab soravtansine-gynx, and glacial acetic acid (0.22 mg), polysorbate 20 (0.1 mg), sodium acetate (0.53 mg), sucrose (90 mg), and Water for Injection. The pH is approximately 5.0. The ELAHERE vial stoppers are not made with natural rubber latex. Close. WebFeb 14, 2024 · mirvetuximab soravtansine-gynx Injection, for Intravenous Use (Elahere™) HCPCS Code J9999 - Not Otherwise Classified, Antineoplastic Drugs: Billing Guidelines; Providers are encouraged to review this information. All bulletin articles, including those related to COVID-19, are available on DHB's Medicaid Bulletin webpage. c# is file or folder

ELAHERE™ (mirvetuximab soravtansine-gynx), FDA Approved for …

WebHow To Use This Tool. This tool allows you to search for the details of a J-code in several ways, including: Drug Name. HCPCS Code. NDC. For example, you can look up a J-code by NDC. Simply type the NDC into the search box. Most J-code detail pages contain a complete HCPCS/NDC crosswalk. This tool is free to use but its contents are not ... WebHCPCS: C9146. NDC(s): 72903-0853-01, Primary Type: Oncology. Route of Administration: Intravenous. About: ELAHERE is an Oncology drug manufactured by Immunogen and … WebAdminister ELAHERE as an intravenous infusion only. Prior to administration, ELAHERE must be diluted with 5% Dextrose Injection, USP to a final concentration of 1 mg/mL to 2 mg/mL. Administer the first dose … diamond supply co jeans

Elahere FDA Approval History - Drugs.com

J-Code Lookup Tool HelloPharmacist

Webublituximab. ublituximab and mirvetuximab soravtansine both increase immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to … WebNov 20, 2024 · Elahere is a first-in-class antibody-drug conjugate directed against FRα, a cell-surface protein highly expressed in ovarian cancer. The antibody is a chimeric IgG1 directed against FRα. The small molecule, DM4, is a microtubule inhibitor designed to kill the targeted cancer cells. It is attached to the antibody via a cleavable linker. cis filingsWebHCPCS CODE HCPCS Code C1834 J0610 J0611 A2024 A2024 A2024 A4341 A4342 A4560 A6590 A6591 A7049 C9145 C9146 C9147 C9148 C9149 E0677 E0711 E1905 J0208 J0218 J0612 J0613 J1411 J1449 J1747 J2403 J9196 ... Inj, elahere, 1 mg Inj, tremelimumab-actl, 1 mg Inj, teclistamab-cqyv, 0.5mg Inj, teplizumab-mzwv, 5 mcg Non … c# is finally called after return

"WebNov 16, 2024 · ELAHERE demonstrated an ORR by investigator of 31.7%, including five complete responses (CRs) The median DOR by investigator was 6.9 months. The drug’s safety has been evaluated from a pooled ... " - Elahere hcpcs

Elahere hcpcs

FOLR1 FDA (ELAHERE™) for Ovarian Carcinoma

WebPrecertification of mirvetuximab soravtansine-gynx (Elahere) is required of all Aetna participating providers and members in applicable plan designs. For precertification of … WebMar 17, 2024 · Common Elahere side effects may include: abnormal lab results; nausea, stomach pain, diarrhea, constipation; fever, mouth sores, skin sores, sore throat, cough; or. pale skin, tiredness, feeling light-headed or short of breath, cold hands and feet. This is not a complete list of side effects and others may occur.

Did you know?

WebFeb 1, 2024 · Outpatient HCPCS (C Codes) C9146 : ... Mirvetuximab soravtansine-gynx (Elahere) is a folate receptor alpha (FR)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with FR positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to … WebELAHERE is a prescription medicine used to treat adults with folate receptor-alpha positive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who: have not …

WebELAHERE for Grade 3 or 4 pneumonitis. (2.4, 5.2) •Peripheral Neuropathy: Monitor patients for new or worsening peripheral neuropathy. Withhold dosage, dose reduce, or … WebMirvetuximab soravtansine (mirvetuximab soravtansine-gynx; Elahere ™) is an antibody-drug conjugate (ADC), which is comprised of a folate receptor α (FRα) directed antibody conjugated to a microtubule inhibitor via a cleavable linker.The ADC is being developed by ImmunoGen for the treatment of FRα expressing cancers.

WebDec 15, 2024 · Effective with date of service Dec. 15, 2024, Medicaid and NC Health Choice programs cover mirvetuximab soravtansine-gynx injection, for intravenous use (Elahere) … WebElahere C9146 Elaprase J1743 Elelyso J3060 Elzonris J9269 Empliciti J9176 Enhertu J9358 Enjaymo J1302 Entyvio J3380 Epogen - ST J0885 ... HCPCS Code Trodelvy J9317 Trogarzo J1746 Tysabri J2323 Tzield C9149 Ultomiris J1303 Unituxin NOC Upliz na J1823 Vabysmo – ST J2777 ...

WebNov 14, 2024 · ELAHERE is the First ADC Approved by FDA for Platinum-Resistant Ovarian Cancer. Indication Covers Patients with One to Three Prior Systemic Treatment Regimens, Regardless of Prior Avastin ® Use. …

WebNov 15, 2024 · The Food and Drug Administration (FDA) has granted accelerated approval to Elahere (mirvetuximab soravtansine-gynx) for the treatment of adult patients with folate receptor alpha (FRα) positive ... diamond supply co hats snapbackWebThe safety of Elahere has been evaluated in a pooled analysis from three studies among a total of 464 patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who received at least one dose of Elahere (6 mg/kg adjusted ideal body weight (AIBW) administered intravenously once every 3 weeks). cis fin svcsWebThe NDC code 72903-853 is assigned by the FDA to the product Elahere which is a human prescription drug product labeled by Immunogen, Inc.. The generic name of Elahere is mirvetuximab soravtansine. The … diamond supply co jacketsWebImmunoGen has priced a 100 mg dose of Elahere at $6,220, CEO Mark Enyedy said on the call. Patients typically receive three to four vials in a cycle of treatment, leaving the cost between ... cis filing deadlinesWeb749 Gateway Street, Suite 502, Building E Abilene, TX 79602. p 325.692.4403. f 325.695.5226. Areas Served View Map diamond supply co hollidaysburg paWebDec 12, 2024 · ELAHERE™ was approved by the U.S. Food and Drug Administration (FDA) on November 14, 2024, under the FDA's accelerated approval program based on objective response rate and duration of response data from the pivotal SORAYA trial. The SORAYA trial was a single-arm study in 106 patients with platinum-resistant ovarian cancer whose … c# is file locked cis fighters